25. Co-Administration of Co-Stimulatory Moieties
- W. John W. Morrow PhD, DSc, FRCPath3,
- Nadeem A. Sheikh PhD4,
- Clint S. Schmidt PhD5,
- D. Huw Davies PhD6
Published Online: 20 JUN 2012
DOI: 10.1002/9781118345313.ch25
Copyright © 2012 Blackwell Publishing Ltd
Book Title
Vaccinology: Principles and Practice
Additional Information
How to Cite
Arancibia-Cárcamo, C. and Latchman, Y. (2012) Co-Administration of Co-Stimulatory Moieties, in Vaccinology: Principles and Practice (eds W. J. W. Morrow, N. A. Sheikh, C. S. Schmidt and D. H. Davies), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781118345313.ch25
Editor Information
- 3
Seattle, WA, USA
- 4
Dendreon Corporation, Seattle, WA, USA
- 5
NovaDigm Therapeutics, Inc., Grand Forks, ND, USA
- 6
University of California at Irvine, Irvine, CA, USA
Publication History
- Published Online: 20 JUN 2012
- Published Print: 3 AUG 2012
ISBN Information
Print ISBN: 9781405185745
Online ISBN: 9781118345313
- Summary
- Chapter
- References
Keywords:
- T cells;
- co-stimulation;
- CD28;
- CTLA4;
- PD1;
- BTLA;
- vaccine;
- tumor;
- viruses;
- autoimmunity
Summary
The use of anti-CTLA4 antibodies and CTLA4Ig clinically has revealed novel therapeutic reagents that might be important in vaccine development. The discovery of new members of the CD28 superfamily such as PD1 and BTLA has broadened our understanding of T-cell activation. Deciphering the uniqueness and overlapping functions of these pathways is essential for uncovering further co-stimulatory moieties for clinical use. In this chapter we will discuss advances in the understanding of co-stimulation through the CD28 superfamily and the potential for the use of agonist/blocking agents as monotherapies or combination therapies in vaccines against cancer, persistent viruses, and autoimmune diseases.